Titan Medical Inc, a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery and Cambridge Design Partnership Ltd. , a leading patient-centric product and technology innovation company specializing in the healthcare sector announce an expanded engagement in respect of the instrument development program for Titan’s single-port robotic surgical system. Additionally, CDP has subscribed for common shares of Titan.

David McNally, President and CEO of Titan, said, “We are pleased to announce our expanded engagement of CDP, and welcome them as a shareholder. Since engaging with them only a few months ago, their highly qualified engineers have leveraged their deep domain experience while demonstrating an ability to understand the exacting requirements of Titan’s robotic surgical system. CDP engineers have improved Titan’s multi-articulating instrument designs with the objective of demonstrating performance improvements, along with the potential for reductions in the target costs of commercial devices.

“The location of CDP’s U.S. office in Raleigh, North Carolina is ideally situated in close proximity to our planned Chapel Hill, North Carolina facility. Yet, CDP’s corporate culture and level of integration with their headquarters in Cambridge, UK allows Titan to draw upon CDP’s depth of experience and breadth of capabilities. Based on early initial indications, and once sufficient additional financing is secured, we envision an expanding role for CDP in the development and manufacturing of surgical instruments and accessories.”

Jez Clements, partner at CDP, said, “We share Titan’s vision for improving patient outcomes with their unique single-port robotic surgical system. We believe the core system architecture to be sound, and once adequate funding is secured, we are confident in the ability of Titan’s management team to resume the development of its single-port robotic system. We are delighted to have the opportunity to apply our deep medical instrument product development experience. It is for these reasons that we are participating with an equity position in the Company.”

About Titan Medical Inc.
Titan Medical Inc. is focused on computer-assisted robotic surgical technologies for application in MIS. The Company is developing a single-port robotic surgical system comprised of a surgeon-controlled patient cart that includes a dual-view camera system with 3D and 2D high-definition vision options and multi-articulating instruments for performing MIS procedures, and a surgeon workstation that provides an advanced ergonomic interface to the patient cart and a 3D endoscopic view inside the patient’s body. Titan intends to initially pursue gynecologic surgical indications for use of its single-port robotic surgical system.

About Cambridge Design Partnership Ltd.
Cambridge Design Partnership is a leading product and technology innovation company focused on helping its customers realise new opportunities. Specialising in the healthcare industry, CDP’s solutions start at the point a business decides upon the need for innovation and finish with the launch of a new product that is patient focused and commercially effective. CDP’s product development and prototype manufacturing quality systems are certified to ISO 13485/9001. For more information, please visit the Company’s website at www.cambridge-design.com.

At CES 2020, Royal Philips , a global leader in health technology, announced its expansion of personalized consumer health solutions that help shape the industry of consumer health. With the expansion of the collaboration with Delta Dental of California to improve oral care outcomes, the introduction of Baby+ to support new parents and the SmartSleep suite of solutions, Philips is addressing people’s individual needs and empowering them to make healthier choices.

“The new generation of digitally savvy health-conscious consumers are demanding intelligent solutions that adapt to their unique needs and lifestyles,” said Roy Jakobs, Chief Business Leader Personal Health businesses at Philips. “By integrating smart devices, software applications and services with cloud-based artificial intelligence, Philips is delivering evidence-based personal health solutions that adapt to a user’s goals, preferences and behaviors, making them more personalized and meaningful than ever before. All our introductions at this year’s CES, such as our oral health, pregnancy and new consumer sleep solutions are part of a connected ecosystem that links proactive personal health engagement with easy access to professional coaching and advice.”

Philips Sonicare oral healthcare ecosystem
Building on the success of Philips’ comprehensive range of world-leading oral healthcare solutions, which includes the top-of-the-range Philips Sonicare DiamondClean Smart connected toothbrush and the Philips Sonicare Teledentistry service, this year’s CES sees the roll-out of the next phase of the BrushSmart® program from Philips and Delta Dental of California, and its affiliates, which comprise the largest provider of dental benefits in the United States. With the mission to improve oral care outcomes, BrushSmart® [1] is designed to connect brushing behaviors at home with professional dental care to better understand, motivate and drive improvements in oral health and overall wellness.

Under the program, members who agree to collect and share real-time oral care brushing data from their Philips Sonicare connected toothbrush will benefit from exclusive oral care product and service offerings, including the Philips Sonicare ExpertClean toothbrush and free brush heads when they brush regularly. Users of the program benefit from better oral health, while Philips and Delta Dental [2] will be able to create data-driven insights and personalized solutions that address the needs of each member. Exemplifying how Philips extends its data driven service from consumers to payers and employers, announcement follows a successful pilot program conducted last year with employees of major U.S. companies, including Web.com, Ultimate Medical Academy and Callaway Golf.

Philips Avent mother and childcare ecosystem
Following the success of Philips free Pregnancy+ app for IOS and Android devices, which currently boasts close to 30 million downloads worldwide, Philips is now introducing another free app called Baby+. While Pregnancy+ is designed to support parents from the moment they know they are expecting a new baby, Baby+ provides them with a dedicated tool to track their baby’s growth and receive ongoing advice specific to each stage of their baby’s development from the moment he or she is born.

Designed in close collaboration with healthcare professionals and existing parents, both apps offer bespoke expert information in the form of articles, information and trackers, bringing a feel-good factor to pregnancy and the first two years of parenthood with beautiful, informative and helpful content, accompanied by clinical back up and expert advice. Baby+, which can track multiple babies in the same family (e.g. twins or closely born siblings) also allows parents to create a yearbook or use the app’s face-a-day function to capture their baby’s growth and share precious moments with other family members. Both apps are free to download from Google Play and the Apple App Store.

In addition, Philips Lumify, an app-based portable ultrasound is showcased. Lumify brings diagnostic capabilities to compatible smart mobile devices, allowing the transducer to connect directly to a phone or tablet, making ultrasound more portable and screenings of pregnant women more easily available.

Philips’ SmartSleep ecosystem
As part of its goal of addressing more than 80% of all sleep issues worldwide, Philips is introducing the latest evolution in its SmartSleep suite of solutions at CES 2020; the SmartSleep Deep Sleep Headband 2. Philips designed the next generation Deep Sleep Headband using consumer sleep data, ongoing research alongside sleep physicians, and feedback from early adopters to deliver an end-to-end sleep experience. The latest model continues to actively improve deep sleep for those who do not get enough sleep due to lifestyle, while introducing new features. New Fall Asleep Sounds help soothe the wearer to sleep, while SmartAlarm helps wake the wearer in their lightest stage of sleep within approximately 5-30 minutes of their desired wake time. The smaller, lighter design also features bone conduction tones replacing over-the-ear speakers, dry sensors, and an improved SleepMapper app experience featuring REM phase tracking for a more robust look at the wearer’s sleep patterns.

Philips will also showcase its SmartSleep Snoring Relief Band solution for alleviating positional back snoring; its SmartSleep Better Sleep Program, which re-trains a user’s sleep habits to help them fall asleep faster and stay asleep longer; and SmartSleep Connected Sleep and Wake-up Light, which enables users to control key aspects of their sleeping and waking experiences with the SleepMapper app. Using Philips’ online SmartSleep Analyzer tool, recently incorporated into the Walgreens Find Care™ platform, consumers can assess their current sleep quality and receive personalized feedback, valuable insights, and recommendations about clinically validated solutions from Philips and its SmartSleep ecosystem partners to help address their sleep challenges.

With a strong foothold and trusted brand in both professional healthcare and the consumer domain, Philips is in a unique position to bridge both worlds – combining clinical know-how with consumer insights to develop solutions and ecosystems that meet the growing and evolving needs of consumers, healthcare professionals and payers/insurers along the full health continuum.

About Royal Philips
Royal Philips is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries.

Southfield, Michigan-based Beaumont Health and Akron, Ohio-based Summa Health have signed a definitive agreement to make Summa Health a subsidiary of Beaumont Health. The arrangement will strengthen both organizations’ ability to partner in new ways to improve the quality of care and the overall health of their communities.

The two organizations signed a Letter of Intent in July and then began an extensive review of both organizations’ clinical, regulatory and financial systems. Signing the definitive agreement is the next step in the process of bringing Summa into the Beaumont family.

“Conversations between leaders and staff at both organizations have been going well. We very much look forward to working even more closely together now that we have a definitive agreement in place,” Beaumont CEO John Fox said. “As we grow our presence in Summa’s market area, our significant investments in our Michigan employees and operations will continue and be further enabled.”

The newly combined organization will utilize the financial strength of both organizations to fund the health system’s overall plan, which includes significant capital and operating projects, to drive ongoing growth in Northeast Ohio and Michigan.

“We are excited to deliver on our shared mission to provide compassionate, quality care and enhance the health of our communities,” said Summa president and CEO Dr. Cliff Deveny. “Our Board is confident that this partnership will further our abilities to not only provide excellent clinical services throughout Northeast Ohio, but also position our leadership, physicians and employees for continued success and growth.”

Summa will retain a local board to support the oversight of clinical operations in Ohio. SummaCare, Summa’s health insurance operation, will remain an integral part of Summa, and the organizations will work together to identify opportunities to drive future expansion.

“Over the past few months, our team has spent a considerable amount of time with the Beaumont team,” Summa Board Chair Anthony Lockhart said. “We believe that by becoming part of the Beaumont family, we will be able to gain efficiencies from being part of a larger organization, further invest in delivering high quality, patient centered care and improve local access to the services most needed by our patients and communities.”

Beaumont Board Chair John Lewis added, “The planned addition of Summa will allow us to serve more people and become a regional health care leader. The efficiencies from transactions of this nature enable us to directly support our medical personnel who provide care ultimately to benefit the patients we serve.”

The organizations are in the process of submitting the agreement to state and federal regulatory agencies for final approval and hope the transaction will close by the end of the first quarter of 2020. Together, the combined organization will have $6.1 billion in total revenue, 45,000 employees and more than 6,000 affiliated physicians.

Beaumont is Michigan’s largest health care system with $4.7 billion in total annual net patient revenue and is most preferred for health care in Southeast Michigan, according to NRC Health survey data.

Summa is one of the largest integrated health care delivery systems in Ohio with total annual revenues of $1.4 billion. The not-for-profit health system employs about 7,000 people and includes a network of four hospitals with a total of 1,300 licensed inpatient beds.
Beaumont Health

Beaumont Health is Michigan’s largest health care system and is most preferred for health care in Southeast Michigan, according to NRC Health survey data. The not-for-profit organization was created to provide patients with greater access to compassionate, extraordinary care, every day. Beaumont Health has a total annual net patient revenue of $4.7 billion and consists of eight hospitals with 3,429 beds, 145 outpatient sites, nearly 5,000 affiliated physicians, 38,000 employees and 3,500 volunteers. In 2018, Beaumont Health had about 178,000 inpatient discharges, 18,000 births and 573,000 emergency visits.
Summa Health

Summa Health is one of the largest integrated healthcare delivery systems in Ohio. Encompassing a network of hospitals, community health centers, a health plan, a physician-hospital organization, a multi-specialty physician organization, research and the Summa Health Foundation, we are nationally renowned for excellence in patient care and for exceptional approaches to healthcare delivery. Summa’s clinical services are consistently recognized by the American Nurses Credentialing Center (Magnet status), U.S. News and World Report and The Leapfrog Group.

The Karadeniz Technical University Farabi Hospital (Karadeniz Teknik Üniversitesi Farabi Hastanesi in Turkish), in Trabzon, Turkey, has 780 beds and 398 investigators. The hospital has seen 1.3 million unique visitors since 1994. Karadeniz Technical University Farabi Hospital currently runs 20 to 30 clinical trials per year.

The hospital’s featured capabilities include computed tomography, neonatal intensive care, radiotherapy, a solid organs and bone marrow transplantation center, magnetic resonance, angiography, coronary intensive care, dialysis units, multi-disciplinary emergency service, surgical intensive care, reanimation units, Interventional Neuroradiology and In-vitro Fertilization center (IVF)

Patients at Karadeniz Technical University Farabi Hospital will have access to international clinical trials bringing world-class quality of care and the most innovative treatments. This results from the fact that the hospital’s EHR will be integrated to Clinerion’s Patient Network Explorer.

This partnership brings the clinical expertise of the hospital’s doctors to Clinerion’s patient network and continues the expansion of Clinerion’s coverage Turkey.

Sponsors and CRO’s will gain access to a new, wider pool of patients from a new geographical region for clinical trials and real-world data. They will benefit from the ability to find and target patients in Trabzon for recruitment in trials and access to innovative treatments. This partnership will drastically reduce the recruitment time and increase potential number of patients recruited into a trial.

“We are pleased that this collaboration will bring many benefits to the Karadeniz Technical University Farabi Hospital,” says Dean Prof. Dr. Mustafa Imamoğlu, “Our hospital will be recognized for contributing to worldwide scientific research. Our patients will be treated more quickly. We will contribute to the national economy through clinical research funding, research related travels and inspections.”

“Clinerion is extremely happy to welcome the Karadeniz Technical University Farabi Hospital to our international patient network, expanding the scope of our patient data offering” says Ian Rentsch, Clinerion CEO. “This opens up a new geographical region for clinical trials in Turkey and brings many expert physicians into our platform.”

Masimo announced that RD SET® sensors with Masimo Measure-through Motion and Low Perfusion™ SET® pulse oximetry have received FDA clearance for improved oxygen saturation (SpO2) accuracy specifications for neonatal patients (< 3 kg).

The updated RD SET® sensors’ SpO2 accuracy specifications have improved significantly, from 3% to 1.5% ARMS (at 1 standard deviation), in conditions of motion and no motion, providing clinicians with even greater confidence when monitoring the oxygenation status of neonates. With this clearance, the improved performance specifications, which were incorporated into RD SET® sensors for patients > 3 kg in 2018, are now available to all patient populations in the United States.

Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved the improved accuracy specifications – providing clinicians with increased sensitivity and specificity to help them make critical patient care decisions.Crucially for newborn health, SET® has been shown to help clinicians reduce severe retinopathy of prematurity in neonates and in multiple studies, including the largest critical congenital heart disease (CCHD) study to date, to improve CCHD screening in newborns.

In addition to offering improved accuracy, RD SET® sensors are designed to enhance patient comfort, optimize clinician workflows, and help hospitals meet green initiatives. The sensors are lightweight and have a flat, soft cable with smooth edges, so that they lie comfortably on a patient’s hand or foot. In particular, RD SET® NeoPt sensors with Velaid SofTouch™ use little to no adhesive, facilitating quick but gentle application and repositioning on the fragile skin of newborns and pre-term babies. RD SET® sensors also feature an intuitive sensor-to-cable connection, while their lightweight design results in up to 84% less waste and their sleek, recyclable packaging reduces storage and shipping space.

Joe Kiani, Founder and CEO of Masimo, said, “We’re delighted to announce the latest result of our continued innovation in our foundational SET® pulse oximetry. We have long been dedicated to helping improve the lives of neonatal, infant, and pediatric patients, and this clearance significantly furthers that mission. Thanks to the brilliance and dedication of our engineers and the continuing support of our customers, we’ve been able to once again raise the standard for pulse oximetry performance. Even though no one has been able to create pulse oximetry that outperforms SET®, we have not allowed that to stop us from continuing our pursuit of perfecting pulse oximetry.”

About Masimo

Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world, and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll. Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius™ PPG, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Doctella™.